Neurocrine Biosciences Inc.
NBIX | NASDAQ
$145.87
-$0.23 (-0.16%)
Nov 2, 2026, 2:09 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 29.49 | 40.15 | 51.47 | 74.19 | 89.65 | 21.93 |
PEG Ratio | 0.71 | 1.22 | 0.87 | 1.07 | -1.15 | 0.02 |
PS Ratio | 4.93 | 5.82 | 6.82 | 7.69 | 7.11 | 8.53 |
PB Ratio | 4.34 | 5.29 | 5.77 | 6.70 | 5.86 | 7.92 |
P/FCF Ratio | 18.85 | 24.60 | 35.60 | 35.44 | 34.56 | 41.01 |
P/OCF Ratio | 18.03 | 23.02 | 33.02 | 33.71 | 31.41 | 39.05 |
OCF/S Ratio | 27.36 | 25.28 | 20.66 | 22.80 | 22.63 | 21.85 |
Debt / Equity Ratio | 0.13 | 0.18 | 0.19 | 0.15 | 0.32 | 0.37 |
Quick Ratio | 3.30 | 3.28 | 2.40 | 2.64 | 3.83 | 5.30 |
Current Ratio | 3.39 | 3.40 | 2.45 | 2.70 | 3.96 | 5.45 |
Asset Turnover | 0.62 | 0.63 | 0.58 | 0.63 | 0.55 | 0.60 |
Interest Coverage | n/a | 4.51 | 54.54 | 35.07 | 3.97 | 4.97 |
Return on Equity | 14.71% | 13.18% | 11.19% | 9.05% | 6.52% | 36.17% |
Return on Assets | 10.33% | 9.18% | 7.68% | 6.52% | 4.32% | 23.48% |
Return on Invested Capital | 10.80% | 12.48% | 6.82% | 8.99% | 4.96% | 10.53% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 98.18% | 98.56% | 97.90% | 98.44% | 98.74% | 99.03% |
Net Profit Margin | 16.73% | 14.49% | 13.23% | 10.38% | 7.90% | 38.94% |
Pretax Profit Margin | 24.66% | 20.63% | 17.60% | 14.37% | 8.95% | 10.20% |
Operating Profit Margin | 21.64% | 24.22% | 13.30% | 16.73% | 9.04% | 15.58% |
FCF Margin | 26.17% | 23.66% | 19.16% | 21.69% | 20.56% | 20.80% |
EBITDA Margin | 23.30% | 27.16% | 22.05% | 15.89% | 12.18% | 14.16% |
Add to Watchlist
Select watchlists to add or remove NBIX